Salivary IgG antibody response to SARS-CoV-2 as a non-invasive assessment of immune response. Differences between vaccinated children and adults

preprint OA: closed
📄 Open PDF Full text JSON View at publisher
AI-generated summary by claude@2026-07, 2026-07-14

Salivary IgG against SARS-CoV-2 reflects systemic immunity in adults, and children exhibit higher salivary antibody levels than adults, suggesting differing local immune responses.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-07, 2026-07-14 · read from full text

This study measured anti–SARS-CoV-2 IgG in matched blood and saliva samples from vaccinated adults to evaluate whether salivary antibody levels could serve as a non-invasive indicator of humoral immune response, and it compared salivary antibody concentrations between vaccinated children and adults. In vaccinated adults, salivary IgG largely mirrored systemic responses, with higher salivary and systemic antibody concentrations associated with prior infection, mRNA-based vaccine schedules, greater exposure history, and shorter time since last exposure; salivary detection was also linked to mRNA-based schedules, time since last exposure, and systemic antibody concentrations. Vaccinated children had higher salivary IgG concentrations than adults even under equal vaccination schedules, exposures, COVID-19 history, and time from last exposure, with younger age, number of exposures, mRNA-based schedules, and shorter time since last exposure associated with salivary IgG levels in multivariable analysis (p<0.0001). The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Background Studies comparing systemic and salivary antibody responses against SARS-CoV-2 between children and adults show conflicting results. Furthermore, it is still unclear whether salivary antibody testing could be a non-invasive approach to evaluate the humoral immune response. Methods anti-SARS-CoV-2 IgG antibodies were measured in blood and saliva sample pairs from vaccinated adults to investigate whether salivary antibody response could be a non-invasive assessment of immune response. Salivary antibody levels were also compared between vaccinated children and adults to investigate local antibody responses. Results Salivary IgG antibody response against SARS-CoV-2 largely reflects the systemic response in vaccinated adults. Salivary and systemic antibody concentrations were higher in vaccinated adults who had been infected, received schedules including mRNA-based vaccines, had more exposures, and a shorter time from last exposure. Salivary antibody detection was associated with schedules including mRNA-based vaccines, time from last exposure, and systemic antibody concentrations. Vaccinated children showed higher salivary antibody concentrations than adults. This difference remained when comparing antibody levels between children and adults under equal conditions (vaccination schedules, number of exposures, time from last exposure, COVID-19 history). Younger age, number of exposures, schedules including mRNA-based vaccines, and shorter time from last exposure were associated with salivary antibody levels in a multivariable linear regression analysis ( p < 0.0001). Conclusions Salivary antibody determination against SARS-CoV-2 could be a non-invasive assessment of the short-term immune response in adults with multiple exposures. Furthermore, the stronger salivary antibody response in children suggests that local immune protection may differ between children and adults, contributing to different outcomes.
Full text 4,472 characters · extracted from oa-doi-fallback · 4 sections · click to expand

Abstract

Background Studies comparing systemic and salivary antibody responses against SARS-CoV-2 between children and adults show conflicting results. Furthermore, it is still unclear whether salivary antibody testing could be a non-invasive approach to evaluate the humoral immune response.

Methods

anti-SARS-CoV-2 IgG antibodies were measured in blood and saliva sample pairs from vaccinated adults to investigate whether salivary antibody response could be a non-invasive assessment of immune response. Salivary antibody levels were also compared between vaccinated children and adults to investigate local antibody responses.

Results

Salivary IgG antibody response against SARS-CoV-2 largely reflects the systemic response in vaccinated adults. Salivary and systemic antibody concentrations were higher in vaccinated adults who had been infected, received schedules including mRNA-based vaccines, had more exposures, and a shorter time from last exposure. Salivary antibody detection was associated with schedules including mRNA-based vaccines, time from last exposure, and systemic antibody concentrations. Vaccinated children showed higher salivary antibody concentrations than adults. This difference remained when comparing antibody levels between children and adults under equal conditions (vaccination schedules, number of exposures, time from last exposure, COVID-19 history). Younger age, number of exposures, schedules including mRNA-based vaccines, and shorter time from last exposure were associated with salivary antibody levels in a multivariable linear regression analysis (p< 0.0001).

Conclusions

Salivary antibody determination against SARS-CoV-2 could be a non-invasive assessment of the short-term immune response in adults with multiple exposures. Furthermore, the stronger salivary antibody response in children suggests that local immune protection may differ between children and adults, contributing to different outcomes. Competing Interest Statement The authors have declared no competing interest. Funding Statement This study was supported by a grant from CONICET (PIP 11220210100378CO). Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was approved by the local Ethics Committee of the Academia Nacional de Medicina I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Footnotes Data availability statement: The data that support the findings of this study are available from the corresponding author upon reasonable request. Funding/Support: This study was supported by a grant from CONICET (PIP 11220210100378CO). Conflict of Interest Disclosure: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Ethics Statement: This study was approved by the Academia Nacional de Medicina Ethics Committee. Consent Statement: Written informed consent was obtained from adult participants and from parents for children participants. More samples were added, so the data and figures were updated. Data Availability All data produced in the present study are available upon reasonable request to the authors Abbreviations - BAU - binding antibody units - BAU/mL - per mL - GMC - geometric mean concentrations - 95% CI - 95% confidence intervals.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2024) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00